Brexit Effect on Biosimilars

The Brexit effect on Biosimilars tends to be negative. Not only would it be a major setback towards approval and launch of biosimilars to the market but also it would be hindrance towards the cost cutting approach taken up by NHS.With Britain being among principal clinical trial centers is owned to see a decrease in the willingness of the manufacturers and researchers to carry out any further trials in Britain. Also Brexit will cause the principal motive of Bristish Biosimilars Association(BBA) to fall back- which aimed at increasing the use of biosimilars.

    Related Conference of Brexit Effect on Biosimilars

    June 06-07, 2018

    International Conference on Pharmaceutical Research and Development

    Philadelphia, Pennsylvania, USA
    June 08-09, 2018

    8th International Conference and Exhibition on GMP, GCP & Quality Control

    Philadelphia, Pennsylvania, USA
    June 08-09, 2018

    7th International conference on Pharmaceutical Auditing

    Philadelphia, Pennsylvania, USA
    June 27-28, 2018

    4th International Conference on Drug Discovery, Designing and Development

    Vancouver, British Columbia, Canada
    August 20-21, 2018

    12th Asian Biologics and Biosimilars Congress

    Tokyo, Japan

    3rd International Conference on Generics Drugs and Biosimilars

    November 15-17, 2018 | Frankfurt, Germany
    October 18-19, 2018

    18th World Pharma Congress

    Warsaw, Poland
    September 18-19, 2018

    6 th European Biopharma Congress

    Amsterdam, Netherlands

    Brexit Effect on Biosimilars Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in